Fig. 1 · Structure

Documents & Downloads

(-)-Huperzine A

Cat. No. A10006 CAS 102518-79-6

GluR inhibitor

(-)-Huperzine A is a naturally occurring sesquiterpene alkaloid compound found in the firmoss Huperzia serrata.

In Stock

Publications for (-)-Huperzine A

1 publication citing this product

  1. Takuya Ohba, .et al. , PharmaNutrition, 2020, 13:100203

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

(-)-Huperzine A inhibits acetylcholinesterase. In a comparative enzyme assay, the parent compound had IC50 values of 0.03 ± 0.00 μM for electric-eel AChE and 68.78 ± 03.15 μM for horse-serum BChE (mean ± SEM, n = 3). These results show selectivity within the tested enzyme panel. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
AChE (G4 form) Ki 7 nM

(-)-Huperzine A Research Summary

This section summarizes 3 in vitro studies and 4 in vivo studies of (-)-Huperzine A from 3 published references.

(-)-Huperzine A In Vitro Studies

In HT22 hippocampal cells, reported natural HupA improved viability and reduced LDH release during glutamate injury. Pretreatment with 10 μM for 24 h reduced ROS after a 5 mM glutamate challenge for 12 h. HupA alone did not significantly reduce MTT viability at 0.1–10 μM, whereas 100 μM reduced viability in the reported control experiment. [2]

In IMR90 human lung fibroblasts, the parent HupA compound was reported as showing no inhibition in the MTT cytotoxicity assay at 10 and 100 μM after 24 h. This result is specific to that cell model and assay. [1]

Cholinesterase inhibition and selectivity

Biochemical assay · Electric-eel acetylcholinesterase (eeAChE) and horse-serum butyrylcholinesterase (eqBChE). [1]

Parent HupA inhibited eeAChE more potently than eqBChE in a modified Ellman assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Electric-eel AChE inhibitionIC50 0.03 ± 0.00 μM[1]
Horse-serum BChE inhibitionIC50 68.78 ± 03.15 μM[1]
Selectivity for eeAChE over eqBChEIC50 ratio 2,273[1]

Literature-Reported Treatment Conditions

Treatment concentration
Initial screen: 10 μM; IC50 curves used 8–10 concentrations (individual values not given in the read methods).
Exposure duration
20 min preincubation at 37 °C; absorbance measured every 20 s for 3 min after substrate addition.
Method
20 μL compound solution, 100 μL pH 8.0 phosphate buffer, 20 μL 3.3 mM DTNB and 40 μL 0.25 U/mL eeAChE; add 20 μL 5 mM ATCI; read 412 nm. BChE assay substitutes eqBChE and BTCI.
Vehicle
Methanol with DMSO as solubilizing agent; methanol negative control.
Co-treatment
None; donepezil hydrochloride monohydrate was a separate positive control.
Reported limits
Final DMSO fraction and individual curve concentrations were not specified. These IC50 values are measurements, not recommended exposures.
Methods and source locations

Compound reported in the paper: (-)-Huperzine A; Compound label in the paper: HupA (1)

Literature experiment on the reported compound; no claim that the authors used or validated Adooq material.

Table 3, compound 1 and footnotes a–e; Biological Studies, AChE and BChE Inhibition Assays; Introduction and Figure 1

Electric-eel AChE inhibition: Ellman assay; mean ± SEM, n = 3. The reported zero SEM is retained as rounded, not interpreted as absence of variation. — Table 3, compound 1 row and footnotes a–b; Biological Studies, AChE and BChE Inhibition Assays

Horse-serum BChE inhibition: Ellman assay with butyrylthiocholine iodide; mean ± SEM, n = 3. — Table 3, compound 1 row and footnotes a, c

Selectivity for eeAChE over eqBChE: Reported IC50(BChE)/IC50(AChE). Not recalculated from rounded IC50 values. — Table 3, compound 1 row and footnote d

IMR90 cell viability

Cell-based study · Human IMR90 lung fibroblasts cultured in DMEM with 10% FBS. [1]

The parent compound had no reported inhibition in the MTT assay at 10 or 100 μM after 24 h.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MTT cytotoxicity at 10 and 100 μM% cytotoxicity n.i. at both concentrations (n.i. = no inhibition)[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 and 100 μM
Exposure duration
24 h
Method
5 × 10^4 cells/well; compounds added after 18 h plating; triplicate wells; MTT incubation 3 h.
Vehicle
Treatment vehicle not specified in the MTT method. DMSO was used to dissolve formazan after treatment.
Co-treatment
None; untreated wells were the reference.
Reported limits
No numerical parent-compound cytotoxicity or detection threshold was reported. Do not treat n.i. as 0% toxicity or general safety.
Methods and source locations

Compound reported in the paper: (-)-Huperzine A; Compound label in the paper: HupA (1)

Literature experiment on the reported compound; no claim that the authors used or validated Adooq material.

Table 4, compound 1 row and footnotes; Biological Studies, Cell Culture and MTT Assay

MTT cytotoxicity at 10 and 100 μM: MTT at 570 nm after 24 h treatment; Table 4 reports mean ± SEM, n = 3; no numerical value for the parent compound. — Table 4, compound 1 row and footnotes a–b; Biological Studies, Cell Culture and MTT Assay

HT22 oxidative glutamate injury

Cell-based study · Immortalized mouse hippocampal HT22 cells; serum-free medium for 2 h before treatment. [2]

HupA improved MTT viability and reduced LDH release during glutamate injury. A 10 μM, 24 h pretreatment reduced ROS after a 5 mM, 12 h glutamate challenge.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Viability and membrane injury after glutamate challengeMTT and LDH Improved viability and reduced LDH release with 0.1, 1 and 10 μM HupA; p < 0.01 versus glutamate-treated group; mean ± SD, n = 8.[2]
Reactive oxygen species after glutamate challengeROS fluorescence Reduced with 10 μM HupA; p < 0.01 versus glutamate-treated group; mean ± SD, n = 8.[2]
HupA-alone viability controlMTT No significant decrease at 0.1, 1 or 10 μM; 100 μM decreased viability (p < 0.01 versus control); mean ± SD, n = 8.[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.1, 1 and 10 μM for viability/LDH protection; 10 μM for ROS; HupA-alone control also included 100 μM.
Exposure duration
10 μM HupA for 24 h, followed by 5 mM glutamate for 12 h is explicit for ROS. Figure 1 reports 24 h HupA treatment, but does not fully specify the sequence for every viability/control group.
Method
Cell-culture exposure; MTT, LDH release and ROS fluorescence.
Vehicle
HupA exposure vehicle not specified in the read methods; DMSO belongs to the MTT formazan step.
Co-treatment
Glutamate injury challenge (5 mM, 12 h), not a therapeutic combination.
Reported limits
HupA washout/continuation during glutamate challenge, vehicle and duration of the 100 μM HupA-alone condition are not explicit. n = 8 is reported, but biological versus technical replicate structure is not defined.
Methods and source locations

Compound reported in the paper: (-)-Huperzine A; Compound label in the paper: HupA

Literature experiment on the reported compound; no claim that the authors used or validated Adooq material.

Introduction; Chemicals and Reagents; Cell Culture and Drug Treatments; MTT/LDH and ROS methods; Figures 1–2 and corresponding Results

Viability and membrane injury after glutamate challenge: MTT at 490 nm and LDH-release assay; no bar heights estimated. — Results, HupA Attenuated Oxidative Damage; Figure 1c–d and caption; MTT/LDH methods

Reactive oxygen species after glutamate challenge: Carboxy-H2DCFDA (20 μM, 1 h); excitation 490 nm, emission 525 nm. — ROS Measurement; Figure 2 and caption

HupA-alone viability control: Figure 1b image and caption; no numerical viability estimated. — Figure 1b and caption; Results, HupA Attenuated Oxidative Damage

(-)-Huperzine A In Vivo Studies

In male CF1 mice, intraperitoneal Hup A lowered brain AChE activity at 1 h and reduced seizures in a 6 Hz challenge. In the dose-response experiment, seizures occurred in 4/12 mice at 0.56 mg/kg and 1/12 at 1 mg/kg, versus 12/12 with vehicle. Effects depended on the challenge: 1 mg/kg shortened the latency to flurothyl-induced myoclonic jerks, and 11/13 treated mice died after the generalized seizure while all vehicle-treated mice survived. [3]

Repeated-dose protection also varied by model. CF1 mice receiving 1 mg/kg/day lost 6 Hz seizure protection by day 12 despite continued AChE inhibition. Scn1aRH/+ mice receiving 1 mg/kg/day remained protected on days 7, 14 and 21, but protection was not maintained 24 h after the last injection. The models were tested at different stimulus currents. [3]

Acute brain AChE pharmacodynamics

Animal study · Male CF1 mice, 6–8 weeks old; right brain hemisphere homogenates. [3]

Brain AChE activity was lower 1 h after Hup A administration; this is a pharmacodynamic endpoint.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Brain AChE activity relative to vehicle% reduction ~25% at 0.10 and 0.18 mg/kg; 63–78% at 0.32–1.8 mg/kg; N = 3–4/dose.[3]

Conditions shared by the study groups

Route
Intraperitoneal injection, 10 mL/kg
Frequency
Single administration
Treatment course
Brain sampled 1 h after injection
Vehicle
10% 2-hydroxypropyl-β-cyclodextrin in sterile 0.9% saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Acute dose-response
0.10, 0.18, 0.32, 0.56, 1 and 1.8 mg/kg
Vehicle, 10% cyclodextrinAChE activity reduced; no drug concentration measured.[3]
Acute dose-response
Model: Male CF1 mice, 6–8 weeks; N = 3–4/dose
Methods and source locations

Compound reported in the paper: (-)-Huperzine A; Compound label in the paper: Hup A

Literature experiment on the reported compound; no claim that the authors used or validated Adooq material.

Methods, Animals, Huperzine A administration and Acetylcholinesterase activity; Figure 1C and caption; first Results section

Brain AChE activity relative to vehicle: Ellman spectrophotometric AChE assay with protein quantification; mean ± SEM; one-way ANOVA with Holm–Šídák comparisons. — Methods, Acetylcholinesterase activity; Results, Hup A protects against induced seizures; Figure 1C

Acute dose-response · Methods, Acetylcholinesterase activity; Figure 1C

Acute 6 Hz seizure challenge

Animal study · Male CF1 mice, 6–8 weeks; corneal stimulation at 6 Hz, 44 mA, 0.2-ms pulses for 3 s. [3]

Hup A reduced seizure occurrence and severity in the 6 Hz challenge, with confirmation in a separate cohort.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Seizure occurrenceMice seizing Vehicle: 12/12; 0.56 mg/kg: 4/12; 1 mg/kg: 1/12.[3]
Complete seizure protection in separate cohortRS0 11/15 (74%) after 1 mg/kg; all vehicle-treated mice had RS2 or RS3 seizures.[3]

Conditions shared by the study groups

Route
Intraperitoneal injection, 10 mL/kg
Vehicle
10% 2-hydroxypropyl-β-cyclodextrin in sterile 0.9% saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Randomized dose-response
0.10, 0.18, 0.32, 0.56 and 1 mg/kg
Each mouse also received vehicleSeizures in 4/12 at 0.56 mg/kg and 1/12 at 1 mg/kg versus 12/12 with vehicle.[3]
Separate confirmation cohort
1 mg/kg
Vehicle crossover condition11/15 (74%) had RS0 after Hup A; all vehicle-treated mice seized.[3]
Randomized dose-response
Model: Male CF1 mice; N = 12
Frequency: One randomized dose or vehicle each week
Treatment course: Six weekly challenge sessions; dose 1 h before each challenge
Separate confirmation cohort
Model: Male CF1 mice; N = 15/treatment
Frequency: Acute treatment in a two-trial crossover, one week apart
Treatment course: Injection 1 h before 44 mA challenge
Methods and source locations

Compound reported in the paper: (-)-Huperzine A; Compound label in the paper: Hup A

Literature experiment on the reported compound; no claim that the authors used or validated Adooq material.

Methods, Animals, Huperzine A administration and 6 Hz psychomotor seizure induction; Results first paragraph; Figure 1A–B

Seizure occurrence: Modified Racine scale; randomized within-mouse dose sequence with weekly challenges. — Methods, 6 Hz psychomotor seizure induction; Results first paragraph; Figure 1A

Complete seizure protection in separate cohort: Modified Racine scale; one-way repeated-measures ANOVA as reported, Dunn post-hoc; Figure 1B p < 0.001. — Results second sentence group; Figure 1B and caption

Randomized dose-response · Methods, 6 Hz psychomotor seizure induction; Figure 1A

Separate confirmation cohort · Methods, 6 Hz psychomotor seizure induction; Figure 1B and corresponding Results

Adverse response in the flurothyl seizure model

Animal study · Male CF1 mice, 6–8 weeks; inhaled flurothyl introduced at 20 μL/min. [3]

Hup A shortened latency to the first myoclonic jerk and did not significantly change latency to generalized tonic-clonic seizures with hindlimb extension. Deaths occurred in 11/13 Hup A-treated mice; all vehicle mice survived.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Myoclonic jerk and GTCS-HLE latenciesDirection and significance Myoclonic jerk latency decreased (p < 0.01); GTCS-HLE latency not significantly changed; N = 13–15/treatment.[3]
Death after GTCS-HLECount 11/13 Hup A-treated mice died; all vehicle-treated mice survived.[3]

Conditions shared by the study groups

Route
Intraperitoneal injection, 10 mL/kg
Frequency
Single administration
Treatment course
Injection 1 h before flurothyl exposure
Vehicle
10% 2-hydroxypropyl-β-cyclodextrin in sterile 0.9% saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Flurothyl challenge
1 mg/kg
VehicleEarlier myoclonic jerk; no significant GTCS-HLE latency shift; 11/13 deaths after GTCS-HLE.[3]
Flurothyl challenge
Model: Male CF1 mice; N = 13–15/treatment
Reported limits: No drug PK or numerical latency values extracted; flurothyl latency test name differs between Methods and caption.
Methods and source locations

Compound reported in the paper: (-)-Huperzine A; Compound label in the paper: Hup A

Literature experiment on the reported compound; no claim that the authors used or validated Adooq material.

Methods, Flurothyl seizure induction; Figure 1F–G and caption; Results paragraph beginning Contrary to the robust Hup A-mediated protection

Myoclonic jerk and GTCS-HLE latencies: Behavioral observation after flurothyl infusion; mean ± SEM. Figure 1F caption specifies unpaired Student’s t-test; Methods lists one-way ANOVA for flurothyl. Test-label discrepancy retained; no numerical latency estimated. — Methods, Flurothyl seizure induction and Statistical analyses; Figure 1F–G and caption

Death after GTCS-HLE: Observed after the induced seizure; no mortality p value supplied in the Results sentence. — Results, paragraph beginning Contrary to the robust Hup A-mediated protection

Flurothyl challenge · Methods, Flurothyl seizure induction; Figure 1F–G; corresponding Results

Repeated-dose 6 Hz protection and loss of effect

Animal study · Male CF1 mice and male Scn1aRH/+ mice (3–5 months, C57BL/6J background); different stimulus currents used for the two models. [3]

Protection during daily dosing depended on the model. CF1 mice lost protection, whereas Scn1aRH/+ mice remained protected on days 7, 14 and 21; protection was not maintained 24 h after the final dose.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CF1 6 Hz response at 44 mAProtection over time 0.5 mg/kg/day: no protection on day 7; 1 mg/kg/day: protection on day 7, not day 12; N = 10/dose.[3]
Scn1aRH/+ 6 Hz response at 24 mAProtection over time N = 9; complete protection on days 7, 14 and 21 (p < 0.01); no significant difference between day 0 and day 22 seizure responses.[3]
Brain AChE activity during repeat dosing in separate CF1 cohorts% reduction Approximately 60% after 7 days at 0.5 mg/kg; approximately 70% after 7 and 12 days at 1 mg/kg; N = 3/group.[3]

Conditions shared by the study groups

Route
Intraperitoneal injection, 10 mL/kg
Frequency
Daily
Vehicle
10% 2-hydroxypropyl-β-cyclodextrin in sterile 0.9% saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
CF1, low-dose course
0.5 mg/kg/day
Day 0 vehicle baselineNo seizure protection on day 7.[3]
CF1, first phase of high-dose course
1 mg/kg/day
Day 0 vehicle baselineProtection on day 7 was lost by day 12. Subsequent escalation phase is not represented.[3]
Scn1aRH/+ course
1 mg/kg/day
Day 0 vehicle baselineComplete protection at days 7, 14 and 21; no maintained protection on day 22.[3]
Separate CF1 PD cohorts
0.5 or 1 mg/kg/day
Vehicle and acute-dose comparatorsAChE inhibition remained despite loss of CF1 seizure protection.[3]
CF1, low-dose course
Model: Male CF1 mice; N = 10; 44 mA challenge
Treatment course: 7 days; challenge 1 h after day 7 injection
CF1, first phase of high-dose course
Model: Male CF1 mice; N = 10; 44 mA challenge
Treatment course: Days 1–12; challenges 1 h after injections on days 7 and 12
Scn1aRH/+ course
Model: Male Scn1aRH/+ mice, 3–5 months; N = 9; 24 mA challenge
Treatment course: 21 days; challenges days 7, 14, 21; off-treatment challenge day 22
Separate CF1 PD cohorts
Model: Male CF1 mice; N = 3/group
Treatment course: 0.5 mg/kg: 7 days; 1 mg/kg: 7 or 12 days
Reported limits: Chronic tissue collection interval is not separately restated in this methods subsection.
Methods and source locations

Compound reported in the paper: (-)-Huperzine A; Compound label in the paper: Hup A

Literature experiment on the reported compound; no claim that the authors used or validated Adooq material.

Methods, Chronic Hup A treatment; Figure 4A–D and caption; Results, Resistance to 6 Hz-induced seizures is maintained...

CF1 6 Hz response at 44 mA: Modified Racine scale; one-way repeated-measures ANOVA and Dunn post-hoc. — Methods, Chronic Hup A treatment; Figure 4A–B and caption

Scn1aRH/+ 6 Hz response at 24 mA: Modified Racine scale; day 22 tested 24 h after last Hup A injection. — Methods, Chronic Hup A treatment; Figure 4D and Results final paragraph of chronic section

Brain AChE activity during repeat dosing in separate CF1 cohorts: Brain AChE assay in separate cohorts; no statistically significant acute-versus-chronic difference reported. — Methods, Chronic Hup A treatment; Figure 4C and corresponding Results

CF1, low-dose course · Methods, Chronic Hup A treatment; Figure 4A

CF1, first phase of high-dose course · Methods, Chronic Hup A treatment; Figure 4B

Scn1aRH/+ course · Methods, Chronic Hup A treatment; Figure 4D and chronic Results

Separate CF1 PD cohorts · Methods, Chronic Hup A treatment; Figure 4C

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 102518-79-6
Applications GluR inhibitor
Formula C15H18N2O
Molecular Weight 242.3
SMILES
C/C=C\1/[C@@H]2CC3=C([C@]1(CC(=C2)C)N)C=CC(=O)N3

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 0.6 mg/mL (2.47 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% propylene glycol, 5% Tween 80, 65% D5W

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

(-)-Huperzine A Research References

  1. [1] Shisanupong Anukanon, Pornkanok Pongpamorn, Wareepat Tiyabhorn, et al. In Silico-Guided Rational Drug Design and Semi-synthesis of C(2)-Functionalized Huperzine A Derivatives as Acetylcholinesterase Inhibitors ACS Omega (2021). PMID: 34368579 DOI: 10.1021/acsomega.1c02875 Source material
  2. [2] Xiao-Yuan Mao, Hong-Hao Zhou, Xi Li, et al. Huperzine A Alleviates Oxidative Glutamate Toxicity in Hippocampal HT22 Cells via Activating BDNF/TrkB-Dependent PI3K/Akt/mTOR Signaling Pathway Cellular and Molecular Neurobiology (2016). PMID: 26440805 DOI: 10.1007/s10571-015-0276-5 Source material
  3. [3] Jennifer C Wong, Stacey B B Dutton, Stephen D Collins, et al. Huperzine A Provides Robust and Sustained Protection against Induced Seizures in Scn1a Mutant Mice Frontiers in Pharmacology (2016). PMID: 27799911 DOI: 10.3389/fphar.2016.00357 Source material

Publications

1 publication citing this product

  1. Takuya Ohba, .et al. , PharmaNutrition, 2020, 13:100203

Added to your cart

View Cart Checkout
Loading...